<chemical> (z)-5-fluoro-2-methyl-1-((4 (methylsulfinyl)phenyl)methylene) 1h-indene-3-acetic acid. A sulfinylindene derivative whose sulfinyl moiety is converted in vivo to an active anti-inflammatory analgesic that undergoes enterohepatic circulation to maintain constant blood levels without causing gastrointestinal side effects.
Pharmacological action: non-steroidal anti-inflammatory agents, cyclooxygenase inhibitors.
Chemical name: 1H-Indene-3-acetic acid, 5-fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-, (Z)-
(12 Dec 1998)
Unknonwn error, please correct. Changed chemical name and the graphic box made an error...
{{Drugbox| |IUPAC_name = (Z)-5-fluoro-2-methyl-1-[[p-(methylsulfinyl)phenyl]methylene]-1H-indene-3-acetic acid | image= Sulindac structure.svg | CAS_number= 38194-50-2 | ATC_prefix= M01 | ATC_suffix= AB02 | PubChem= 5352 | Drug
Sulindac is a Non-steroidal anti-inflammatory drug
Like other NSAIDs, it is useful in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted in the body to the active NSAID. More specifically, the agent is converted by liver enzymes to a sulfide that is excreted in the bile and then reabsorbed from the intestine. This is thought to help maintain constant blood levels with reduced gastrointestinal side effects. Some studies have shown sulindac to be relatively less irritating to the stomach than other NSAID's except for drugs of the COX-2 inhibitor
Its usual dosage is 150-200 milligrams twice per day, with food. It should not be used by persons with a history of major allergic reactions (urticaria or anaphylaxis) to Aspirin
Sulindac seems to have a property, independent of COX-inhibition, of reducing the growth of polyps and precancerous lesions in the colon, especially in association with familial adenomatous polyposis, and may have other anti-cancer properties.[1]
Sulindac is an effective tocolytic and may be used in the treatment of preterm labour. In common with other NSAIDs, sulindac is currently being investigated for its role in the treatment of Alzheimer's disease.
Since it was found that the sulfoxide functional group can be reduced by methionine sulfoxide reductase A (MsrA), a possible anti-oxidative capability is being discussed.
This article is based on an article from Wikipedia, the free encyclopedia and is available
under the terms of
GNU Free Documentation License.
In the Wikipedia there is a
list with all authors of this article
available.
Comments for Sulindac:
No Comments found for Sulindac